MedTrace Logo

Canakinumab for Pyoderma Gangrenosum

NCT01302795 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2016-09-27

No results posted yet for this study

Summary

This study is a prospective open label evaluation of Canakinumab (Ilaris) for treatment of subjects with pyoderma gangrenosum.

Conditions

  • Pyoderma Gangrenosum

Interventions

DRUG

Canakinumab

Monoclonal antibody inhibiting interleukin 1 beta

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Lars French, Prof MD · University Hospital Zurich, Division of Dermatology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2014-08-31
Completion
2015-11-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01302795 on ClinicalTrials.gov